

主要学会 前立腺癌関連演題一覧

ASCO-GU 2021 重要演題一覧

ASCO-GU 2021はCOVID-19の影響によりバーチャルイベントとして開催されたが、例年通り非常に多くの前立腺癌関連の発表がなされた。今回は、そのなかから本誌編集主幹・委員4名により特に重要な演題を選出し、掲載する。

なお、すべての前立腺癌関連演題の一覧は、右のQRコードもしくは下記のURLからアクセス可能なので、是非ご参照いただきたい。

https://med.m-review.co.jp/espoir_detail?id=4&convention_id=1

※ Abstract Noの下の★の数は、4名の本誌編集主幹・委員のうちその演題を重要演題として選出した人数を表している。



Abstract No	Title	1st Author
▶6 ★★	177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).	Michael S Hofman
▶8 ★★	Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC).	Felix Y Feng
▶9 ★★★★	Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).	Dana E. Rathkopf
▶10 ★★★★	KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.	Leonard Joseph Appleman
▶11 ★★★★	Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).	Kim N. Chi
▶12 ★★★	CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.	Karim Fizazi
▶13 ★★★	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.	Johann S. De Bono
▶25 ★	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.	Hanna Tukachinsky
▶26 ★★★★	Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.	Kim N. Chi
▶27 ★★★	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.	Nobuaki Matsubara
▶32 ★	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREDY) : A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.	Jeremy C. Durack
▶33 ★	PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa) : A phase III study (CONDOR) —A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.	Frederic Pouliot
▶36 ★	18F-DCFPyL PSMA PET imaging compared to conventional imaging in the detection of pelvic nodal metastases in patients with locally advanced or oligometastatic prostate cancer.	Ashanda Rosetta Patrice Esdaille
▶39 ★	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).	Matthew D Tucker
▶41 ★	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.	Vaibhav G. Patel
▶48 ★★	Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.	Oliver A. Sartor
▶53 ★	Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.	Daniel M. Geynisman
▶56 ★	Cognitive status of prostate cancer (PCa) patients aged 60 years and older after a six-month gonadotropin-releasing hormone agonist (GnRHα) therapy, according to age groups: Secondary analysis of PRISME study.	Morgan Roupret